Upadacitinib effectiveness in moderate‐to‐severe atopic dermatitis: A real‐life multicentre and retrospective study
Australasian Journal of Dermatology · 2023
DOI: 10.1111/ajd.14164 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Australasian Journal of Dermatology, 2023. Verfasst von F Javier Melgosa Ramos und 5 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital Doctor Peset of Valencia, Valencia, Spain. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 13 Literaturangaben. Gefördert von: AbbVie.
Abstract (Originalsprache)
This was an observational and retrospective multicentre study conducted on adolescents and adults diagnosed with moderate‐to‐severe atopic dermatitis (AD) and treated with upadacitinib. Disease severity was measured by Eczema Area and Severity Index (EASI), validated investigator global assessment for AD and pruritus Numerical Rating Scale (NRS) at baseline and Weeks 4, 16, 24 and 52 (when available). Twenty‐one patients were included. All patients had previously received topical and systemic corticosteroids. Rapid response to upadacitinib was observed: Mean (SD) EASI score was 19.8 (6.5) at baseline, and 3.1 (4.2), 0.9 (1.4), 0.6 (0.6) and 0.6 (0.6) at the Weeks 4, 16, 24 and 52, respectively. Itch was controlled at Week 4 in all patients (mean [SD] NRS score 7.6 [1.9] baseline, 1.5 [1.3] W4). Severe infections or major adverse cardiovascular events were not reported. We highlight effectiveness and rapid response of upadacitinib in achieving itch control even in long‐standing recalcitrant cases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University Hospital Doctor Peset of Valencia, Valencia, Spain.
- Clinic University Hospital of Valencia, Valencia, Spain.
- University Hospital Virgen de los Lirios, Alcoy, Spain.
ORCID-Profile: F Javier Melgosa Ramos, Víctor González-Delgado
Förderung
- AbbVie
Zitieren
APA
Melgosa Ramos, F. J., González-Delgado, V., Motilla, J. M. S., Marta, G. P., Mateu Puchades, A., & Sergio, S. A. (2023). Upadacitinib effectiveness in moderate‐to‐severe atopic dermatitis: A real‐life multicentre and retrospective study. Australasian Journal of Dermatology. https://doi.org/10.1111/ajd.14164
Vancouver
Melgosa Ramos FJ, González-Delgado V, Motilla JMS, Marta GP, Mateu Puchades A, Sergio SA. Upadacitinib effectiveness in moderate‐to‐severe atopic dermatitis: A real‐life multicentre and retrospective study. Australasian Journal of Dermatology. 2023. doi:10.1111/ajd.14164
BibTeX
@article{MelgosaRamos2023,
author = {Melgosa Ramos, F Javier and González-Delgado, Víctor and Motilla, José María Sánchez and Marta, Galarreta Pascual and Mateu Puchades, Almudena and Sergio, Santos Alarcón},
title = {Upadacitinib effectiveness in moderate‐to‐severe atopic dermatitis: A real‐life multicentre and retrospective study},
journal = {Australasian Journal of Dermatology},
year = {2023},
doi = {10.1111/ajd.14164}
}
EUVIMED